{
    "ticker": "RMTI",
    "name": "Rockwell Medical, Inc.",
    "description": "Rockwell Medical, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for the treatment of end-stage renal disease (ESRD) and chronic kidney disease (CKD). Founded in 1996 and headquartered in Wixom, Michigan, Rockwell Medical is dedicated to improving the quality of life for patients undergoing dialysis through its proprietary product offerings. The company\u2019s lead product, Triferic, is the first and only FDA-approved therapy that provides iron to patients in conjunction with dialysis, addressing the common issue of iron deficiency in this population. In addition to Triferic, Rockwell Medical is actively developing other therapies aimed at enhancing patient care and outcomes in the renal space. Their commitment to research and development is evident in their robust pipeline, which includes therapies for anemia management and other complications associated with kidney disease. Rockwell Medical partners with healthcare providers to deliver effective treatment solutions while ensuring patient safety and quality of care. The company\u2019s mission is to transform the treatment landscape for kidney disease patients and to be a leader in the renal care market, thereby making a significant impact on patient health and well-being.",
    "industry": [
        "Biotechnology",
        "Healthcare"
    ],
    "headquarters": "Wixom, Michigan, USA",
    "founded": "1996",
    "website": "https://www.rockwellmedical.com",
    "ceo": "Robert L. Chioini",
    "social_media": {
        "twitter": "https://twitter.com/RockwellMed",
        "linkedin": "https://www.linkedin.com/company/rockwell-medical/"
    },
    "investor_relations": "https://www.rockwellmedical.com/investor-relations/",
    "key_executives": [
        {
            "name": "Robert L. Chioini",
            "position": "CEO"
        },
        {
            "name": "James H. Sweeney",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Triferic"
            ]
        },
        {
            "category": "Dialysis Products",
            "products": [
                "Dialysate"
            ]
        }
    ],
    "seo": {
        "meta_title": "Rockwell Medical, Inc. | Innovative Therapies for Kidney Disease",
        "meta_description": "Learn about Rockwell Medical, Inc., a leader in developing therapies for kidney disease. Discover their innovative products and commitment to patient care.",
        "keywords": [
            "Rockwell Medical",
            "Kidney Disease",
            "Dialysis",
            "Triferic",
            "Biotechnology",
            "Healthcare"
        ]
    },
    "faq": [
        {
            "question": "What is Rockwell Medical known for?",
            "answer": "Rockwell Medical is known for its innovative therapies for kidney disease, particularly its lead product Triferic."
        },
        {
            "question": "Who is the CEO of Rockwell Medical?",
            "answer": "Robert L. Chioini is the CEO of Rockwell Medical, Inc."
        },
        {
            "question": "Where is Rockwell Medical headquartered?",
            "answer": "Rockwell Medical is headquartered in Wixom, Michigan, USA."
        },
        {
            "question": "What is Triferic?",
            "answer": "Triferic is the first and only FDA-approved therapy that provides iron to patients during dialysis."
        },
        {
            "question": "When was Rockwell Medical founded?",
            "answer": "Rockwell Medical was founded in 1996."
        }
    ],
    "competitors": [
        "KPTI",
        "BAX",
        "NXGN"
    ],
    "related_stocks": [
        "AMGN",
        "ABT",
        "VRTX",
        "BMY"
    ]
}